Broader aspirin professional labeling indications urged by joint advisory committee.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN PROFESSIONAL LABELING INCLUSION OF STABLE ANGINA PECTORIS was one of several recommendations made by FDA's Nonprescription Drugs and Cardiovascular & Renal Drugs Advisory Committees at a joint meeting Jan. 23 in Gaithersburg, Md. The joint advisory committee also voted to recommend that professional labeling for aspirin include an indication for prevention of recurrent vascular events including myocardial infarction (MI) and stroke and use in people who have had revascularization for symptomatic coronary disease.
You may also be interested in...
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care